H.C. Wainwright analyst Ram Selvaraju maintains $Rhythm Pharmaceuticals (RYTM.US)$ with a buy rating, and adjusts the target price from $64 to $69.
According to TipRanks data, the analyst has a success rate of 46.4% and a total average return of 9.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Rhythm Pharmaceuticals (RYTM.US)$'s main analysts recently are as follows:
The firm is enhancing its expectations for IMCIVREE's Phase 3 trial success in HO following recent obesity week observations and has incorporated risk-adjusted projections for RM-718/LB54640 within the company's MC4R portfolio. It is anticipated that the company's stock will experience an upswing as it approaches several significant milestones in 2025.
The launch of BBS continues to demonstrate strong and steady growth, evidenced by 100 new US prescriptions and 80 reimbursement approvals in the third quarter. The company's pipeline is advancing towards significant milestones.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
